- PR Newswire•45 minutes agoFDA Grants Roche Label Extension for the cobas® EGFR Mutation Test v2 for use with Plasma as a Companion Diagnostic for TAGRISSO™
PLEASANTON, Calif., Sept. 29, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX, RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension of the cobas ® EGFR ...
- Investor's Business Daily•2 days ago
The FDA could approve a breakthrough adult eczema treatment from Regeneron and Sanofi as soon as March.
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||31.31 - 31.62|
|52wk Range||29.89 - 35.13|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||23.47|
|Avg Vol (3m)||904,979|
|Dividend & Yield||1.02 (3.24%)|